Mp54-02 two-year efficacy follow-up of a phase i trial of intravesical bacillus calmette-guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous bacillus calmette-guérin treatment
Journal of Urology（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要